Does booster influenza vaccination improve vaccination efficacy in patients with quiescent systemic lupus erythematosus?

Completed

• Conditions: systemische lupus erythematosus; lupus; 10003816

• Registration Number: NL-OMON31124
• Lead Sponsor: niversitair Medisch Centrum Groningen

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 13 May 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 82

Inclusion Criteria

Patients
- patients have to fulfil international disease criteria of SLE
- quiescent disease, defined as SLEDAI <=5
- informed consent;Healthy controls
- informed consent

Exclusion Criteria

Patients
- active disease, defined as SLEDAI >5
- use of prednisone >30 mg/day
- pregnancy
- malignancy
- no informed consent;Healthy controls
- use of immunosuppressives
- malignancy
- pregnancy
- no informed consent

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Seroprotection rate (the percentage of SLE patients with a titre equal to or<br /><br>greater than 40 against all three vaccine strains) in SLE patients after two<br /><br>influenza vaccinations as compared to a single vaccination.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>1. Seroconversions and fourfold titre rises after 4 weeks and after 8 weeks.<br /><br>2. Geometric mean titres after four weeks and after 8 weeks</p><br>